Angel News
Angel News

Back to Homepage

20th May 2022

Oxford Drug Design receives £2.2m from existing investors and angels

Oxford Drug Design Limited (ODD), a biotechnology company with a proprietary computational and machine learning platform, has raised £2.2M in funding from existing investors ACF Investors, o2h Ventures, Meltwind Advisory, a number of returning angels and new investors and the US-based R42 Group. This brings the firm’s total amount of grant and equity funding to over £10M. 


Register / Login now to read full story

In order to read the full story we need you to be registered with us, please click the links below to login or register.

Login / Register

Add a comment:




Enter the characters in the image shown:

Back to Homepage